Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
16 hedge funds and large institutions have $426K invested in Agile Therapeutics in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 12 closing their positions.
26% more capital invested
Capital invested by funds: $337K → $426K (+$88.7K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
27% less funds holding
Funds holding: 22 → 16 (-6)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$649K |
| 2 |
State Street
Boston,
Massachusetts
|
+$57.7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14.4K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$4.03K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$128 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$92.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$53.4K |
| 3 |
VF
Virtu Financial
New York
|
-$27K |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$18.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.2K |
AGRX Hedge Fund Activity: Q2 2023 in Review
16 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q2 2023, worth a combined $426K — up 26% from $337K a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of AGRX and 6 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 2 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $649K. The largest seller was LPL Financial, exiting entirely with an estimated $92.2K sold.
- 16 institutional investors held Agile Therapeutics (AGRX) as of Q2 2023, down from 22 in Q1 2023.
- Funds reported $426K of Agile Therapeutics stock for Q2 2023, up 26% quarter-over-quarter.
- 6 funds opened new Agile Therapeutics positions in Q2 2023 and 12 closed out, a net change of -6 holders.
- The largest Agile Therapeutics buyer in Q2 2023 was Armistice Capital, an estimated $649K added.
- The largest Agile Therapeutics seller in Q2 2023 was LPL Financial, an estimated $92.2K sold.
Based on aggregated 13F filings for Q2 2023.